Phase 3 pivotal program in MESI – PEAK and PINNACLE Study Design PEAK PINNACLE Primary endpoint BCVA change from baseline to the average of Week 20 and 24 Key secondary endpoints Time to 15 letter gain Time to 15 letter gain Time to 15 letter loss Weeks D1 4 8 12 16 20 24 28 32 36 40 44 48 KSI-101 5 mg (n~50) KSI-101 10 mg (n~50) Sham (n~50) Primary endpoint KSI-101 5 mg injection Sham injection KSI-101 10 mg injection Individualized treatment (PRN) Sham PRN Fixed monthly dosing Individualized dosing PEAK and PINNACLE are actively enrolling 92